27.7 USD
+0.34 (+1.24%)
27.7 USD
0 (0%)
AMPH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make AMPH suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year AMPH was profitable.
In the past year AMPH had a positive cash flow from operations.
AMPH had positive earnings in each of the past 5 years.
Each year in the past 5 years AMPH had a positive operating cash flow.
1.2 Ratios
AMPH has a Return On Assets of 6.70%. This is amongst the best in the industry. AMPH outperforms 88.54% of its industry peers.
AMPH has a Return On Equity of 14.37%. This is amongst the best in the industry. AMPH outperforms 89.06% of its industry peers.
AMPH's Return On Invested Capital of 8.51% is amongst the best of the industry. AMPH outperforms 86.98% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 12.71%.
The 3 year average ROIC (12.92%) for AMPH is well above the current ROIC(8.51%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROIC | 8.51% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
1.3 Margins
AMPH's Profit Margin of 15.43% is amongst the best of the industry. AMPH outperforms 88.02% of its industry peers.
In the last couple of years the Profit Margin of AMPH has grown nicely.
AMPH's Operating Margin of 20.73% is amongst the best of the industry. AMPH outperforms 87.50% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
AMPH's Gross Margin of 49.36% is fine compared to the rest of the industry. AMPH outperforms 63.02% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% |
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
2. Health
2.1 Basic Checks
AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AMPH has less shares outstanding
AMPH has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AMPH has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.44 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
AMPH's Altman-Z score of 2.44 is fine compared to the rest of the industry. AMPH outperforms 65.10% of its industry peers.
The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.49, AMPH belongs to the top of the industry, outperforming 81.25% of the companies in the same industry.
A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
The Debt to Equity ratio of AMPH (0.78) is worse than 69.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Altman-Z | 2.44 |
ROIC/WACC1
WACC8.52%
2.3 Liquidity
A Current Ratio of 3.12 indicates that AMPH has no problem at all paying its short term obligations.
With a Current ratio value of 3.12, AMPH perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
A Quick Ratio of 2.21 indicates that AMPH has no problem at all paying its short term obligations.
AMPH's Quick ratio of 2.21 is in line compared to the rest of the industry. AMPH outperforms 44.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.95%.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 61.62% on average per year.
The Revenue has decreased by -0.03% in the past year.
Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
3.2 Future
The Earnings Per Share is expected to grow by 0.50% on average over the next years.
The Revenue is expected to grow by 4.23% on average over the next years.
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
AMPH is valuated reasonably with a Price/Earnings ratio of 8.05.
Based on the Price/Earnings ratio, AMPH is valued cheaply inside the industry as 92.71% of the companies are valued more expensively.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 7.44, which indicates a rather cheap valuation of AMPH.
93.23% of the companies in the same industry are more expensive than AMPH, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.59, AMPH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.05 | ||
| Fwd PE | 7.44 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 91.15% of the companies listed in the same industry.
AMPH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AMPH is cheaper than 89.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.6 | ||
| EV/EBITDA | 7.62 |
4.3 Compensation for Growth
The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
5. Dividend
5.1 Amount
No dividends for AMPH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
27.7
+0.34 (+1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners71.91%
Inst Owner Change0.4%
Ins Owners9.28%
Ins Owner Change3.46%
Market Cap1.29B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target33.05 (19.31%)
Short Float %11.87%
Short Ratio9.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-2.41%
PT rev (3m)0%
EPS NQ rev (1m)1.91%
EPS NQ rev (3m)-1.22%
EPS NY rev (1m)-0.38%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)-2.29%
Revenue NQ rev (3m)-2.52%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.05 | ||
| Fwd PE | 7.44 | ||
| P/S | 1.78 | ||
| P/FCF | 11.6 | ||
| P/OCF | 8.46 | ||
| P/B | 1.66 | ||
| P/tB | 6.3 | ||
| EV/EBITDA | 7.62 |
EPS(TTM)3.44
EY12.42%
EPS(NY)3.72
Fwd EY13.45%
FCF(TTM)2.39
FCFY8.62%
OCF(TTM)3.27
OCFY11.82%
SpS15.55
BVpS16.7
TBVpS4.4
PEG (NY)N/A
PEG (5Y)0.13
Graham Number35.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.7% | ||
| ROE | 14.37% | ||
| ROCE | 10.26% | ||
| ROIC | 8.51% | ||
| ROICexc | 10.49% | ||
| ROICexgc | 20.29% | ||
| OM | 20.73% | ||
| PM (TTM) | 15.43% | ||
| GM | 49.36% | ||
| FCFM | 15.35% |
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | 5.49 | ||
| Debt/EBITDA | 3 | ||
| Cap/Depr | 78.19% | ||
| Cap/Sales | 5.71% | ||
| Interest Coverage | 6.36 | ||
| Cash Conversion | 75.12% | ||
| Profit Quality | 99.44% | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 2.44 |
F-Score5
WACC8.52%
ROIC/WACC1
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-11.92%
EPS Next 2Y-1.77%
EPS Next 3Y1.01%
EPS Next 5Y0.5%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-1.41%
Revenue Next 2Y2.05%
Revenue Next 3Y2.4%
Revenue Next 5Y4.23%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-1.68%
EBIT Next 3Y1.08%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%
AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ
What is the fundamental rating for AMPH stock?
ChartMill assigns a fundamental rating of 6 / 10 to AMPH.
Can you provide the valuation status for AMPHASTAR PHARMACEUTICALS IN?
ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.
Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?
AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.
How financially healthy is AMPHASTAR PHARMACEUTICALS IN?
The financial health rating of AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6 / 10.
What is the expected EPS growth for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?
The Earnings per Share (EPS) of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -11.92% in the next year.